SCHEMBL22988852

SCHEMBL22988852

CC(C)(C)C(=O)NC(=O)Nc1ccc(Cc2c[nH]c3ncccc23)cn1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CSF1R P07333 4/20 0.54
▸ KIT P10721 2/20 0.54
▸ MET P08581 1/20 0.48
▸ GPR84 Q9NQS5 2/20 0.47
▸ FGFR1 P11362 1/20 0.43
▸ FGFR4 P22455 1/20 0.43
▸ MTNR1A P48039 1/20 0.43
▸ CYP2C19 P33261 5/20 0.39
▸ CYP3A4 P08684 4/20 0.39
▸ HDAC1 Q13547 1/20 0.38
▸ PDPK1 O15530 1/20 0.37
▸ MAP2K1 Q02750 1/20 0.37
▸ LCK P06239 1/20 0.37
▸ PGR P06401 1/20 0.37
▸ CHRM2 P08172 1/20 0.37
▸ HTR1A P08908 1/20 0.37
▸ ADRA2A P08913 1/20 0.37
▸ PDGFRB P09619 1/20 0.37
▸ ADORA3 P0DMS8 1/20 0.37
▸ CHRM1 P11229 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22988861 0.91 CSF1R (0.51) CSF1RKITMETGPR84FGFR1
SCHEMBL22988853 0.87 CSF1R (0.52) CSF1RKITMETGPR84FGFR1
SCHEMBL22988851 0.86 CSF1R (0.47) CSF1RKITCYP2C19CYP3A4LCK
SCHEMBL22988854 0.84 CYP3A4 (0.56) CSF1RKITCYP2C19CYP3A4LCK
SCHEMBL22988842 0.83 GPR84 (0.49) CSF1RKITMETGPR84FGFR1
SCHEMBL22988850 0.83 CSF1R (0.58) CSF1RKITFGFR1FGFR4MTNR1A
SCHEMBL22988847 0.83 CSF1R (0.46) CSF1RKITCYP2C19CYP3A4LCK
SCHEMBL22988857 0.82 CSF1R (0.49) CSF1RKITMTNR1ACYP2C19CYP3A4
SCHEMBL1268213 0.82 CSF1R (0.59) CSF1RKITMETGPR84FGFR1
SCHEMBL22988859 0.81 CSF1R (0.47) CSF1RKITMTNR1ACYP2C19CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2018233526-A9 CSF1R INHIBITOR, AND MANUFACTURING METHOD THEREFOR AND APPLICATION THEREOF 上海和誉生物医药科技有限公司 2021-02-18 — — WO disclosed
US-20160340361-A1 PIPERIDINE INHIBITORS OF JANUS KINASE 3 AUSPEX PHARMACEUTICALS, INC. 2016-11-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160340361-A1 PIPERIDINE INHIBITORS OF JANUS KINASE 3 JAK2, JAK3, PAK3 CSF1R 1210/4885KIT 360/4885MET 1384/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback